Press release
EKTERLY A Comprehensive Forecast on the Accelerating Market Growth for Hereditary Angioedema by 2034
Are you interested in finding out the projected market size of EKTERLY in 2034? EKTERLY Market Forecast
https://www.delveinsight.com/report-store/ekterly-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=gpr
Key Factors Driving EKTERLY Growth
1. Market Share Gains and New Patient Starts
• EKTERLY (sebetralstat) is quickly gaining traction in the hereditary angioedema (HAE) on-demand treatment market, fueled by its distinction as the first and only oral therapy for acute HAE attacks.
• Since its launch, new patient initiations have increased rapidly, with early commercial data showing hundreds of patient start forms in the U.S. within months of approval, highlighting both a strong unmet need and robust prescription adoption.
• KalVista's commercial approach, featuring focused physician education and patient support programs, is effectively boosting awareness and adoption of EKTERLY among HAE specialists and general immunologists.
2. Expansion Across Key Indications
• Hereditary Angioedema (HAE) Acute Attacks: EKTERLY is approved for the treatment of acute HAE attacks in adults and adolescents aged 12 and older, providing a novel first-line oral therapy option.
• Pediatric Expansion: Ongoing clinical studies are evaluating EKTERLY in children aged 2-11, potentially broadening its label and eligible patient population.
• Broader HAE Use: With growing clinical and real-world evidence, treatment guidelines may increasingly endorse early on-demand oral therapy, further expanding EKTERLY's clinical adoption.
• Future Indications: Ongoing regulatory submissions in key markets could enable broader global access to EKTERLY in the future.
The EKTERLY Market Report offers projected sales forecasts for EKTERLY for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
KalVista Pharmaceutical's EKTERLY is serving as a beacon of hope for the patients suffering from Hereditary Angioedema.
EKTERLY Recent Developments
• In November 2025, KalVista Pharmaceuticals reported new findings on patient satisfaction and pediatric outcomes from its clinical trials of EKTERLY (sebetralstat), the first and only oral, on-demand therapy for hereditary angioedema (HAE). The company also shared results from physician and patient surveys and a consensus study underscoring the significant unmet need for safe, effective, and convenient on-demand HAE treatments. These data were presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting.
What is an EKTERLY Prescribed for?
EKTERLY is prescribed for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell malignancies. It is a bispecific antibody therapy designed to engage CD3 on T cells and CD20 on malignant B cells, helping the immune system recognize and destroy cancer cells, especially in patients who have not responded to standard therapies.
The report extensively covers the details and developments related to EKTERLY, capturing important highlights on developmental pipeline, regulatory status and special designations of EKTERLY, route of administration, safety and efficacy details.
Do you know your drug's competitive positioning against EKTERLY? EKTERLY Drugs Insights
https://www.delveinsight.com/sample-request/ekterly-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=gpr
EKTERLY Market Assessment
This report provides a detailed market assessment of EKTERLY for Hereditary Angioedema in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2034.
EKTERLY Clinical Assessment
The report provides the clinical trials information of EKTERLY for Hereditary Angioedema covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
EKTERLY Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the EKTERLY.
EKTERLY Market Size in the US
A dedicated section of the report focuses on the expected market size of EKTERLY for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of EKTERLY:
• The report contains forecasted sales of EKTERLY for indication till 2034.
• Comprehensive coverage of the late-stage emerging therapies for Hereditary Angioedema.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for EKTERLY in Hereditary Angioedema.
Stay ahead in competition by leveraging insights on EKTERLY market Report: Download the latest sample for EKTERLY Market Report
https://www.delveinsight.com/sample-request/ekterly-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=gpr
Why you should buy EKTERLY Market Report:
• The report provides future market assessments for EKTERLY for Hereditary Angioedema in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading EKTERLY for Hereditary Angioedema forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EKTERLY
• Discover the competitive landscape of EKTERLY through 7MM
• Get a Thorough Analysis of the EKTERLY Development pipeline, Safety & Efficacy of the EKTERLY, and ROA
• Thorough EKTERLY market forecast will help understand how drug is competing with other emerging EKTERLY
• Get analysis of the EKTERLY clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Hereditary Angioedema Pipeline https://www.delveinsight.com/sample-request/ekterly-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=gpr
DelveInsight's, "Hereditary Angioedema Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Hereditary Angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release EKTERLY A Comprehensive Forecast on the Accelerating Market Growth for Hereditary Angioedema by 2034 here
News-ID: 4360472 • Views: …
More Releases from DelveInsight Business Research
Retinitis Pigmentosa Pipeline 2026: FDA Approvals and Clinical Trials Landscape …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Retinitis Pigmentosa pipeline constitutes 20+ key companies continuously working towards developing 25+ Retinitis Pigmentosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Retinitis Pigmentosa Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinitis Pigmentosa Market.
The Retinitis…
Multiple Sclerosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Car T Cell Therapy For Multiple Myeloma Pipeline 2026: MOA, ROA, FDA-Approved Dr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into…
Spinocerebellar Ataxias Pipeline 2026: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
More Releases for EKTERLY
Venture Capital Firms Chase US$200 Billion US Rare Disease Market
The US rare disease drug market is quickly becoming one of the most attractive areas for venture capital investment, fueled by breakthroughs in gene therapy, precision medicine, and favorable regulatory support for orphan drugs. While each rare disease affects a relatively small number of patients, the sector collectively represents a market opportunity approaching $200 billion. With more than 7,000 rare diseases identified worldwide and only a limited number of approved…
Hereditary Angioedema Market to Surpass USD 3 Billion by 2034 Across 7MM | 10+ C …
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hereditary Angioedema market report also covers emerging drugs, current treatment practices, Hereditary Angioedema market share of the individual therapies, current and forecasted Hereditary Angioedema Market…
Hereditary Angioedema Market Forecast 2034 - Competitive Landscape, Clinical Tri …
Hereditary Angioedema Companies are Takeda, CSL Behring, Intellia Therapeutics, Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, BioMarin Pharmaceutical, Pharvaris Netherlands B.V, Shire, and others
Hereditary Angioedema Market Summary
The Hereditary Angioedema market, valued at approximately USD 3 billion in 2023, is expected to experience strong growth driven by the approval of new treatment options. Hereditary Angioedema is a rare genetic condition characterized by recurrent episodes of severe swelling in the face, limbs, gastrointestinal…
Hereditary Angioedema Clinical Trials Analysis 2025: Novel Therapeutics, Prophyl …
DelveInsight's "Hereditary Angioedema (HAE) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline designed to prevent and manage acute HAE attacks. Despite available C1-INH replacement therapies and bradykinin receptor antagonists, patients continue to face unpredictable, sometimes life-threatening attacks, emphasizing the need for more effective and convenient treatment options.
The HAE pipeline is progressing with next-generation C1-INH formulations, oral kallikrein inhibitors, and gene-targeted therapies that aim for long-term prophylaxis. Combination…
United States Infectious Diseases Treatment Market Trends: Key Players, Innovati …
Market Size and Growth:
The Global Infectious Diseases Treatment Market size reached US$ 189.09 Billion in 2024 from US$ 182.65 Billion in 2023 and is expected to reach US$ 264.75 Billion by 2033, growing at a CAGR of 3.9% during the forecast period 2025-2033.
The Infectious Diseases Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable…
Immunology Drugs Market Poised for Breakthrough Growth Amid Rising Autoimmune an …
Market Size and Growth:
The Global Immunology Drugs Market Size reached US$ 91.97 billion in 2023 and is expected to reach US$ 148.62 billion by 2031, growing at a CAGR of 6.35% during the forecast period 2024-2031.
The Immunology Drugs Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants…
